1. Risk of Thrombosis in Adult Philadelphia-Positive ALL Treated with an Asparaginase-Free ALL Regimen.
- Author
-
Ruiqi Chen, Xing Liu, Law, Arjun D., Kanfar, Solaf, Maze, Dawn, Chan, Steven M., Gupta, Vikas, Yee, Karen W., Minden, Mark D., Schimmer, Aaron D., Schuh, Andre C., McNamara, Caroline J., Murphy, Tracy, Xu, Anna, Falcone, Umberto, Seki, Jack, and Sibai, Hassan
- Subjects
- *
THROMBOSIS , *THROMBOEMBOLISM , *LYMPHOBLASTIC leukemia , *ADULTS , *ACUTE leukemia - Abstract
Background: venous thromboembolism (VTE) is a well-known complication in adults with acute lymphoblastic leukemia (ALL), especially in patients treatedwith asparaginase (ASNase)-including regiments. However, VTE risk in adult Philadelphia-positive ALL (Ph+ve ALL) patients treated with non-hyperCVADchemotherapy is unclear. In this study, we examinedVTE incidence in adult Ph+veALL patients treated with imatinib plus a pediatric-inspired asparaginase (ASNase)-free regimen modified from the Dana Farber Cancer Institute (DFCI) ALL protocol. Methods: a single centre retrospective review of Ph+ve ALL patients treated at Princess Margaret Cancer Center (PMCC) from 2008-2019 with imatinib plus modified DFCI protocol was conducted. Results: of the 123 patients included, 30 (24.3%) had at least 1 radiology confirmed VTE event from diagnosis to the end of maintenance therapy. 86.7% (26/30) of the VTE events occurred during active treatment. Of all VTE events, the majority (53.3%) were DVT and/or PE while another significant portion were catheter-related (40.0%). Major bleeding was observed in 1 patient on VTE treatment with low molecular weight heparin (LMWH). Conclusion: a high VTE incidence (24.3%) was observed in adults Ph+ve ALL patients treated with imatinib plus an ASNase-free modified DFCI pediatric ALL protocol, suggesting prophylactic anticoagulation should be considered for all adult Ph+ve ALL patients including those treated with ASNase-free regimens. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF